In contrast, the EGFR monoclonal antibody, cetuximab, had a modest therapeutic effect on the KRAS wild-type cholangiocarcinoma xenograft (TFK-1), but not the KRAS mutated xenograft (HuCCT1). This evidence concerns the gene KRAS and cholangiocarcinoma.